VizOptik, eye drops 0.05% 15 ml

Alpha-adrenomimetic. It has a vasoconstrictor and anti-edema effect.

When used topically it reduces conjunctival edema, burning sensation, painful mucous membrane of the eyes, lacrimation.

The drying effect develops within a few minutes and lasts for 4-8 hours.

Pharmacokinetics

Systemic absorption is low when used topically.

Indications

Active ingredient

Composition

In 1 ml of eye drops contains:

Active substance

Excipients

Boric acid,

sodium tetraborate decahydrate,

dinatrium edetate dihydrate,

benzalkonium chloride,

purified water.

How to take, the dosage

Apply 1-2 drops 2-3 times daily into the lower conjunctival sac of the affected eye.

If there is no improvement within 48 hours, further use of the drug should be discontinued and a physician consulted.

Interaction

Simultaneous use with MAO inhibitors, tricyclic antidepressants, guanethidine may cause arterial hypertension, tachycardia.

Concomitant use with reserpine, insulin, propranolol, general anesthetic agents, atropine increases the risk of cardiovascular effects of tetrizolin.

Concomitant use with guanethidine may provoke mydriasis with temporary visual impairment.

Special Instructions

VizOptic should only be used if there is mild eye irritation. If conjunctival irritation and hyperemia are associated with an infectious disease, foreign body or chemical trauma of the cornea, an ophthalmologist should be consulted.

If within 48 hours of starting eye drops, symptoms persist, become more severe, or if there are side effects, discontinue use and consult an ophthalmologist.

If you experience intense eye pain, headache, visual disturbances, sudden “floating spots” in front of the eyes, red eyes, pain when exposed to light, or double vision, seek medical attention immediately.

If contact lenses are worn, they should be removed before the drug is applied and reinserted 15 minutes afterwards. Direct contact of the eye drops with soft contact lenses should be avoided due to possible loss of transparency.

The drug should not be used concomitantly with MAOI inhibitors (including phenelzine, nialamide, iproniazid) and within 10 days after stopping their administration.

Impact on driving and operating machinery

At the time of treatment, care must be taken when driving motor vehicles and engaging in other potentially dangerous activities requiring increased concentration, rapid psychomotor reactions and good vision (after using eye drops pupil dilation and feeling of blurred vision may occur).

Contraindications

With caution:

Side effects

Topical

Elevated intraocular pressure, a burning sensation, and reactive ocular hyperemia.

Rarely, dilation of the pupil.

Systemic reactions

High blood pressure, hyperglycemia, heart disturbances, headache, nausea, drowsiness, weakness, tremor, dizziness, insomnia, tachycardia, allergic reactions.

Overdose

The development of systemic symptoms of overdose is possible if the drug is accidentally or intentionally taken orally or if the dosage is exceeded when used topically.

Symptoms: dilation of the pupil, nausea, cyanosis, fever, convulsions, arrhythmias, arterial hypertension, pulmonary edema, dyspnea. Excessive systemic absorption of imidazole derivatives may lead to CNS depression accompanied by somnolence, hypothermia, bradycardia, collapse, apnea and coma.

The risk of overdose symptoms associated with drug absorption is high in young children, especially if swallowed. Overdose in children may appear as CNS depression accompanied by somnolence, excessive sweating, severe hypotension, up to and including shock.

Treatment: administer activated charcoal, gastric lavage, oxygen inhalation, use of antipyretic and anticonvulsants. For BP decrease phentholamine 5 mg in 0.9% sodium chloride solution is used slowly v/v or 100 mg orally. A specific antidote is unknown.

Pregnancy use

VizOptic is contraindicated in children under 3 years of age. Pregnancy and lactation are prescribed with caution.

Similarities